Open Payments

AULTMAN HOSPITAL

Type
Teaching hospital
Where
Canton, OH
Medicare CCN
360084
Received
$1,128,020 in 141 records, 2019 ($75,138 general, $1,052,882 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment52$75,138
2019Research payment89$1,052,882

By company

CompanyRecordsAmountYears
TESARO, Inc.13$405,9612019
Amgen Inc.13$214,7672019
Novartis Pharmaceuticals Corporation6$200,0722019
Eli Lilly and Company1$71,6832019
Boston Scientific Corporation23$54,8802019
AstraZeneca Pharmaceuticals LP8$40,9862019
PFIZER INC.17$28,7592019
American Regent5$25,7442019
Biosense Webster, Inc.1$20,2442019
Kowa Research Institute, Inc.4$10,4322019
Abbott Laboratories6$9,0102019
Medical Device Business Services, Inc.4$7,5002019
Daiichi Sankyo Inc.1$6,1052019
SANOFI US SERVICES INC.1$5,0002019
GE HEALTHCARE1$4,5332019
ZOLL Medical Corporation2$2,9002019
Merck Sharp & Dohme LLC2$1,3462019
E.R. Squibb & Sons, L.L.C.2$1,2832019
Boehringer Ingelheim Pharmaceuticals, Inc.1$1,2502019
Janssen Biotech, Inc.1$1,2502019
Lilly USA, LLC1$1,2502019
JAZZ PHARMACEUTICALS INC.1$1,2502019
TAIHO ONCOLOGY, INC.1$1,2502019
Bayer Healthcare Pharmaceuticals Inc.1$1,2502019
Pharmacyclics LLC, an AbbVie Company1$1,2502019
EMD Serono, Inc.1$1,2502019
Genentech USA, Inc.1$1,2502019
Astellas Pharma US Inc1$1,2502019
Ipsen Biopharmaceuticals, Inc1$1,2502019
Agios Pharmaceuticals, Inc.1$1,2502019
Medline Industries LP1$5002019
Sterilmed, Inc.11$4222019
Medical Graphics Corporation1$2262019
Janssen Pharmaceuticals, Inc1$2002019
CSL Behring1$2002019
Olympus America Inc.3$1802019
Masimo Corporation1$822019

By nature of payment

NatureRecordsAmount
Research payment89$1,052,882
Space rental or facility fees (teaching hospital only)24$27,862
Education4$24,276
Grant5$15,227
Compensation for services other than consulting, including serving as faculty or as a speaker at a v13$5,615
Charitable Contribution2$1,750
Gift4$407

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31AstraZeneca Pharmaceuticals LP$802Research paymentIn-kind items and servicesStudy of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small Cell Lung Cancer NSCLC NEPTUNE2019
2019-12-31Masimo Corporation$82EducationIn-kind items and servicesSET and rainbow SET Device, Devices2019
2019-12-31AstraZeneca Pharmaceuticals LP$82Research paymentIn-kind items and servicesA Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval2019
2019-12-25Amgen Inc.$3,030Research paymentCash or cash equivalentRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-12-19Sterilmed, Inc.$39Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-12-16Boston Scientific Corporation$1,791Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTASAP TOO2019
2019-12-16Boston Scientific Corporation$1,756Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTASAP TOO2019
2019-12-16Boston Scientific Corporation$400Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTIMPERIAL2019
2019-12-11Amgen Inc.$1,255Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC2019
2019-12-05Abbott Laboratories$1,200Research paymentCash or cash equivalentABSORB Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-12-03Kowa Research Institute, Inc.$4,290Research paymentCash or cash equivalent DrugK-877-3022019
2019-11-28PFIZER INC.$221Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-11-22Medline Industries LP$500Charitable ContributionCash or cash equivalent2019
2019-11-22Kowa Research Institute, Inc.$448Research paymentCash or cash equivalent DrugK-877-3022019
2019-11-21TESARO, Inc.$40,143Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-11-19Sterilmed, Inc.$39Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-11-18Boston Scientific Corporation$125Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-11-08American Regent$520Research paymentCash or cash equivalentINJECTAFER Drug, AnemiaHeart_FID2019
2019-11-04Boston Scientific Corporation$1,321Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTIMPERIAL2019
2019-11-04Boston Scientific Corporation$845Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTASAP TOO2019
2019-10-30TESARO, Inc.$53,524Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-10-25Kowa Research Institute, Inc.$3,933Research paymentCash or cash equivalent DrugK-877-3022019
2019-10-23Sterilmed, Inc.$36Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-10-21Boston Scientific Corporation$16,439Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-10-09American Regent$6,180Research paymentCash or cash equivalentINJECTAFER Drug, AnemiaHeart_FID2019
2019-10-07EMD Serono, Inc.$1,250Charitable ContributionCash or cash equivalentBavencio Biological, Oncology2019
2019-10-01Kowa Research Institute, Inc.$1,760Research paymentCash or cash equivalent DrugK-877-3022019
2019-09-25TESARO, Inc.$40,143Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-09-19Pharmacyclics LLC, an AbbVie Company$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentImbruvica Drug, Oncology2019
2019-09-19Medical Device Business Services, Inc.$1,100GrantCash or cash equivalent2019
2019-09-18Janssen Biotech, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentErleada Drug, Oncology2019
2019-09-16Boston Scientific Corporation$1,512Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTASAP TOO2019
2019-09-16Boston Scientific Corporation$440Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTIMPERIAL2019
2019-09-14TESARO, Inc.$1,262Space rental or facility fees (teaching hospital only)Cash or cash equivalentZEJULA Drug, ONCOLOGY2019
2019-09-14Novartis Pharmaceuticals Corporation$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-09-14Novartis Pharmaceuticals Corporation$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentVOTRIENT Drug, ONCOLOGY2019
2019-09-13Boston Scientific Corporation$586Research paymentCash or cash equivalentACUITY Device, TACHYNAVIGATE X4 STUDY2019
2019-09-13Medical Graphics Corporation$226Gift (2 payments)In-kind items and services2019
2019-09-12TESARO, Inc.$26,762Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-09-05Abbott Laboratories$650Research paymentCash or cash equivalentABSORB Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-09-04Sterilmed, Inc.$20Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-08-30Boston Scientific Corporation$7,727GrantIn-kind items and servicesILab Device, Imaging2019
2019-08-29PFIZER INC.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentBOSULIF Drug, METABOLIC DISEASE;ONCOLOGY2019
2019-08-28TESARO, Inc.$40,143Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-08-28PFIZER INC.$616Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-19TESARO, Inc.$40,143Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-08-16E.R. Squibb & Sons, L.L.C.$33Research paymentCash or cash equivalentELIQUIS Drug, CardiovascularAn Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K A2019
2019-08-14PFIZER INC.$663Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-08-13AstraZeneca Pharmaceuticals LP$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentCALQUENCE Drug, Oncology2019
2019-08-07Amgen Inc.$1,382Research paymentIn-kind items and servicesNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC2019
2019-08-05Boston Scientific Corporation$3,582Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTASAP TOO2019
2019-08-05Boston Scientific Corporation$2,200Research paymentCash or cash equivalentINGEVITY Device, BRADYINGEVITY2019
2019-08-05Boston Scientific Corporation$200Research paymentCash or cash equivalentINGEVITY Device, BRADYINGEVITY2019
2019-08-01Sterilmed, Inc.$14Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-07-29Lilly USA, LLC$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-07-29Merck Sharp & Dohme LLC$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentKEYTRUDA Biological, ONCOLOGY2019
2019-07-19TAIHO ONCOLOGY, INC.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentLonsurf Drug, Oncology2019
2019-07-17TESARO, Inc.$40,143Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-07-16TESARO, Inc.$40,995Research paymentCash or cash equivalentZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-07-11JAZZ PHARMACEUTICALS INC.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-07-10Boehringer Ingelheim Pharmaceuticals, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-07-08American Regent$7,659Research paymentCash or cash equivalentINJECTAFER Drug, AnemiaHeart_FID2019
2019-07-05Bayer Healthcare Pharmaceuticals Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentXofigo Drug, Oncology2019
2019-07-02PFIZER INC.$1,623Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-06-29Daiichi Sankyo Inc.$6,105Research paymentCash or cash equivalentEnhertu Drug, OncologyDS8201AU2012019
2019-06-27GE HEALTHCARE$4,533Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-06-26PFIZER INC.$616Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-06-26Sterilmed, Inc.$83Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-06-24SANOFI US SERVICES INC.$5,000Research paymentCash or cash equivalentSAR439954 DrugA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotaglifloz2019
2019-06-20Agios Pharmaceuticals, Inc.$1,250EducationCash or cash equivalentIDHIFA Drug, ONCOLOGY2019
2019-06-19TESARO, Inc.$40,143Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-06-18Astellas Pharma US Inc$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentXTANDI Drug, ONCOLOGY2019
2019-06-18Merck Sharp & Dohme LLC$96Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg2019
2019-06-14Boston Scientific Corporation$1,316Research paymentCash or cash equivalentACUITY Device, TACHYNAVIGATE X4 STUDY2019
2019-06-07Abbott Laboratories$2,750Research paymentCash or cash equivalentABSORB Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-06-07Abbott Laboratories$950Research paymentCash or cash equivalentABSORB Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-06-06AstraZeneca Pharmaceuticals LP$2,700Research paymentCash or cash equivalentA Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durval2019
2019-06-03Boston Scientific Corporation$2,000Research paymentCash or cash equivalentACUITY Device, TACHYNAVIGATE X4 STUDY2019
2019-05-31Amgen Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentBlincyto Biological, Oncology2019
2019-05-29PFIZER INC.$663Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-05-29Sterilmed, Inc.$61Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-05-28Genentech USA, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentAvastin Biological, BioOncology2019
2019-05-25Amgen Inc.$12,395Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC2019
2019-05-23Ipsen Biopharmaceuticals, Inc$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentSOMATULINE DEPOT Drug, Oncology/Endocrinology2019
2019-05-22Amgen Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentNeulasta Biological, Oncology2019
2019-05-20TESARO, Inc.$13,381Research paymentIn-kind items and servicesZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-05-20Boston Scientific Corporation$4,500Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial ProductPREEMPT HF2019
2019-05-20ZOLL Medical Corporation$200Space rental or facility fees (teaching hospital only)Cash or cash equivalent Device, DEFIBRILLATOR2019
2019-05-17Medical Device Business Services, Inc.$4,000GrantCash or cash equivalent2019
2019-05-15PFIZER INC.$221Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-05-13E.R. Squibb & Sons, L.L.C.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentOPDIVO Biological, Oncology2019
2019-05-06Abbott Laboratories$660Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-05-03Amgen Inc.$114,972Research paymentIn-kind items and servicesRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-04-29ZOLL Medical Corporation$2,700EducationCash or cash equivalent Device, DEFIBRILLATOR2019
2019-04-25Sterilmed, Inc.$10Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-04-23Biosense Webster, Inc.$20,244EducationIn-kind items and servicesCarto 3 System Device, Cardiology2019
2019-04-22Boston Scientific Corporation$5,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTASAP TOO2019
2019-04-22Boston Scientific Corporation$540Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTIMPERIAL2019
2019-04-22Boston Scientific Corporation$400Research paymentCash or cash equivalentINGEVITY Device, BRADYINGEVITY2019
2019-04-19Janssen Pharmaceuticals, Inc$200Space rental or facility fees (teaching hospital only)Cash or cash equivalentXARELTO Drug, Cardiovascular & Metabolism2019
2019-04-17AstraZeneca Pharmaceuticals LP$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentIMFINZI Drug, Cardiovascular and Metabolism2019
2019-04-10PFIZER INC.$10,640Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-04-10American Regent$2,777Research paymentCash or cash equivalentINJECTAFER Drug, AnemiaHeart_FID2019
2019-04-10PFIZER INC.$2,600Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-04-10PFIZER INC.$1,400Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-04-10PFIZER INC.$1,359Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-04-10PFIZER INC.$826Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-04-10PFIZER INC.$616Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-04-04AstraZeneca Pharmaceuticals LP$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLYNPARZA Drug, Oncology2019
2019-04-02Medical Device Business Services, Inc.$1,400GrantCash or cash equivalent2019
2019-04-02CSL Behring$200Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-03-28Amgen Inc.$750Research paymentIn-kind items and servicesRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-03-27Amgen Inc.$1,212Research paymentCash or cash equivalentRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-03-26Sterilmed, Inc.$79Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-03-23Olympus America Inc.$119GiftIn-kind items and servicesOlympus Vent Tubes Device, ENT Products2019
2019-03-23Olympus America Inc.$46GiftIn-kind items and servicesOlympus Vent Tubes Device, ENT Products2019
2019-03-23Olympus America Inc.$14GiftIn-kind items and services Device, Surgical Endoscopy Products2019
2019-03-20PFIZER INC.$628Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-03-18Boston Scientific Corporation$880Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTIMPERIAL2019
2019-03-18Boston Scientific Corporation$715Research paymentCash or cash equivalentACUITY Device, TACHYNAVIGATE X4 STUDY2019
2019-03-15Sterilmed, Inc.$11Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-03-13Abbott Laboratories$2,800Research paymentCash or cash equivalentAbsorb Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-03-08Medical Device Business Services, Inc.$1,000GrantCash or cash equivalent2019
2019-03-05TESARO, Inc.$23,174Research paymentCash or cash equivalentZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-03-04Novartis Pharmaceuticals Corporation$7,478Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARA MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ62019
2019-02-26TESARO, Inc.$6,000Research paymentCash or cash equivalentZEJULA Drug, ONCOLOGYA PHASE 3 COMPARISON OF PLATINUM-BASED THERAPY WITH TSR-042 AND NIRAPARIB VERSUS STANDARD OF CARE PLATINUM-BASED THERAPY2019
2019-02-21Novartis Pharmaceuticals Corporation$1,520Research paymentCash or cash equivalentKISQALI Drug, ONCOLOGYAN OPEN LABEL MULTICENTER PHASE IIIB STUDY OF RIBOCICLIB LEE011 IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTM2019
2019-02-20PFIZER INC.$663Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-02-13PFIZER INC.$4,148Research paymentCash or cash equivalentA PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOST2019
2019-02-11Amgen Inc.$50,139Research paymentIn-kind items and servicesRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-02-04Novartis Pharmaceuticals Corporation$16,930Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARA 24 WEEK RANDOMIZED DOUBLE BLIND MULTI CENTER PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFECT OF LCZ696 O2019
2019-01-29Amgen Inc.$26,091Research paymentCash or cash equivalentRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-01-28Novartis Pharmaceuticals Corporation$171,644Research paymentCash or cash equivalentENTRESTO Drug, CARDIOVASCULARPROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT 2019
2019-01-24AstraZeneca Pharmaceuticals LP$14,710Research paymentCash or cash equivalentStudy of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small Cell Lung Cancer NSCLC NEPTUNE2019
2019-01-24Sterilmed, Inc.$25Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-01-22Boston Scientific Corporation$600Research paymentCash or cash equivalentACUITY Device, TACHYNAVIGATE X4 STUDY2019
2019-01-21American Regent$8,608Research paymentCash or cash equivalentINJECTAFER Drug, AnemiaHeart_FID2019
2019-01-15AstraZeneca Pharmaceuticals LP$17,941Research paymentCash or cash equivalentBRILINTA Drug, Cardiovascular and MetabolismA Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice dai2019
2019-01-08Eli Lilly and Company$71,683Research paymentCash or cash equivalentA RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD2019
2019-01-07Amgen Inc.$515Research paymentIn-kind items and servicesRepatha Biological, CardiologyFOURIER OLE (Ph 4)2019
2019-01-03Amgen Inc.$525Research paymentIn-kind items and servicesNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Stark CountyCanton city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Canton, OH, county Stark County, OH, state Ohio; placed by its city name.

MeasurePlace (city or town)
Canton, OH
County
Stark County, OH
State
Ohio
Population B0100369,755373,71311,810,293
Population, 2020 census P170,872374,85311,799,448
Median age B0100235.241.839.7
Under 18 B0100125.4%21.5%22.0%
65 and over B0100115.7%20.5%18.3%
Households B1100129,302155,9554,863,191
Foreign born B050022.5%2.2%5.2%
Median household income B19013$43,188$67,934$71,389
Median family income B19113$53,992$86,156$92,749
Per capita income B19301$24,690$36,762$40,552
Poverty rate B1700127.4%12.5%13.3%
Unemployment rate B230257.8%3.9%4.8%
Civilian labor force B2302532,390186,7135,994,779
Mean commute (minutes) B0801319.121.723.4
Bachelor's degree or higher B1500316.4%25.9%31.5%
Housing units B2500133,836167,9495,292,391
Owner-occupied B2500348.7%69.2%67.2%
Renters B2500351.3%30.8%32.8%
Median home value B25077$97,800$186,400$214,800
Median gross rent B25064$850$909$1,034
White, not Hispanic B0300259.0%83.8%75.8%
Black B0300223.4%7.1%12.0%
Hispanic or Latino B030026.7%3.0%4.8%
Asian B030020.6%0.9%2.5%
American Indian and Alaska Native B030020.0%0.1%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Canton, OH.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.